title: [A pilot study of the reduced effects of adverse events caused by oral morphine and oxycodone after rotating to fentanyl patch in patients with metastatic breast cancer].
abstract: BACKGROUND
  It has been confirmed by several clinical trials that the fentanyl patch causes less adverse events than sustained-release oral morphine, and after rotation. However, there has been no evidence comparing the fentanyl patch with controlled-release oral oxycodone in terms of adverse events.
  
  
  OBJECTIVE
  We prospectively investigated the reduced effects of adverse events caused by sustained-release oral morphine and controlled-release oxycodone after rotating to the fentanyl patch in patients with metastatic breast cancer.
  
  
  METHODS
  Metastatic breast cancer patients requiring sustained-release oral morphine or controlled-release oral oxycodone(n=9, 2 taking oral morphine, 7 taking oral oxycodone, mean age, 57. 5 years)were recruited. Those experiencing adverse events from oral morphine or oral oxycodone were administered a fentanyl patch.
  
  
  RESULTS
  The pain score was reduced significantly at the 4th week. The fentanyl patch was associated with significantly less nausea, vomiting, constipation, sleepiness and dizziness over the study period.
  
  
  CONCLUSIONS
  This study suggested that the fentanyl patch can reduce adverse events caused by sustained-release oral morphine as well as controlled-release oral oxycodone.
authors.affiliation: Dept. of Breast and Thyroid Surgery, Fukuyama City Hospital.
authors.forename: Masahiko
authors.initials: M
authors.lastname: Ikeda
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Sonoo
authors.forename: Junichi
authors.initials: J
authors.lastname: Kurebayashi
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Oota
authors.forename: Sayaka
authors.initials: S
authors.lastname: Fujii
authors.forename: Toshirou
authors.initials: T
authors.lastname: Shimo
authors.forename: Akiko
authors.initials: A
authors.lastname: Mizutou
authors.forename: Mari
authors.initials: M
authors.lastname: Seki
authors.forename: Wataru
authors.initials: W
authors.lastname: Saitou
authors.forename: Tetsumasa
authors.initials: T
authors.lastname: Yamashita
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Koike
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Yamamoto
authors.forename: Shigeo
authors.initials: S
authors.lastname: Shiiki
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Nakashima
authors.forename: Katsuhiro
authors.initials: K
authors.lastname: Tanaka
authors.forename: Tsunehisa
authors.initials: T
authors.lastname: Nomura
authors.forename: Shinichirou
authors.initials: S
authors.lastname: Kubo
mesh_terms: D000279:Administration, Cutaneous; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000150:complications* / Q000473:pathology; D004359:Drug Therapy, Combination / Q000009:adverse effects; D005260:Female; D005283:Fentanyl / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D009020:Morphine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D009362:Neoplasm Metastasis; D010098:Oxycodone / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D010146:Pain / Q000188:drug therapy* / Q000209:etiology; D010865:Pilot Projects; D011446:Prospective Studies; D057968:Transdermal Patch
chemical_list: D009020:Morphine; D010098:Oxycodone; D005283:Fentanyl